Corganics Joins CMS Innovation Center Demonstration to Advance CBD Integration in Patient Care
Corganics is pleased to announce that Corganics Clinical CBD products are included for use within the CMS Innovation Center’s Substance Access Beneficiary Engagement Incentive (BEI) under the Enhancing Oncology Model (EOM), effective April 1, 2026.
In parallel, Corganics is completing a partnership with the largest and most respected oncology practices in the United States to support implementation of this demonstration, positioning the company at the forefront of CBD integration within supportive oncology care. This collaboration, focused on expanding patient access to high-quality, clinically aligned CBD products, marks a crucial step forward in advancing quality of life and reducing overall cost of care.
Corganics, which works exclusively with healthcare professional practices, hospital systems, and academic centers, is positioned to play a pivotal role in establishing CBD as a meaningful therapeutic option.
Strategic Significance
- Expands Corganics’ direct access to leading oncology practices through CMS-aligned EOM participants.
- Embeds within a national value-based care model, accelerating institutional adoption.
- Establishes a first-mover advantage in federally recognized CBD utilization.
- Provides a scalable, non-opioid solution aligned with demand for safer symptom management.
- Access up to $500 per eligible patient annually through the current BEI programs
Why Corganics Supports BEI
Corganics supports this CMS initiative as a critical step toward expanding access to safe, compliant, non-opioid options for patients managing cancer-related symptoms such as pain, neuropathy, anxiety, and sleep disruption.
Corganics products meet or exceed stringent federal and state requirements for inclusion in this demonstration, for example:
- ≤0.3% delta-9 THC (federally compliant hemp)
- Non-inhalable, clinically appropriate formats
- Rigorous third-party testing for potency and safety
- Production in a cGMP and FDA-registered facility
By aligning with the BEI demonstration framework, Corganics is helping enable physician-guided, evidence-informed use of CBD within a structured, outcomes-driven environment where real-world evidence can be evaluated to better understand patient impact. This aligns seamlessly with Corganics’ healthcare-focused commercial strategy.
As adoption of EOM and BEI expands, Corganics is positioned to scale as the trusted, healthcare-exclusive CBD partner both in conjunction with federal programs and beyond.